

(c) the amino acid sequence (III) (SEQ ID NO:3)

N-W-E-L-A-D-Q-P-Q-N-L-E-E-I-L-M-H-C-Q-T,

(d) the amino acid sequence (IV) (SEQ ID NO:4)

T-L-K-Y-A-I-K-T-G-H-P-R-Y-F-N-Q-L-S-T-G,

(e) the amino acid sequence (V) (SEQ ID NO:5)

P-R-Y-F-N-Q-L-S-T-G-L-D-M-Y-G-L-A-A-D-W,

(f) the amino acid sequence (VI) (SEQ ID NO:6)

T-Y-E-I-A-P-V-F-V-L-L-E-Y-V-T-L-K-K-M-R,

(g) the amino acid sequence (VII) (SEQ ID NO:7) [(IV) (SEQ ID NO:4)]

F-F-R-M-V-I-S-N-P-A-A-T-H-Q-D-I-D-F-L-I,

(h) partial regions of the amino acid sequence shown in (a), (b), (c),

(d), (e), (f) or/and (g) with a length of at least 6 amino acids or/and

(i) amino acid sequences which have an essentially equivalent

specificity or/and affinity of binding to MHC molecules as the amino acid sequences shown in (a), (b), (c), (d), (e), (f), (g) or/and (h);

wherein said peptide or peptide derivative has a length of up to 25 amino acids.

REMARKS

The amendment is supported by the specification at page 5, lines 13-14.

In the event this paper is not timely filed, applicants hereby petition for an appropriate extension of time. The fee for this extension may be charged to our

RECEIVED
MAR 27 2000
TC 1600 MAIL ROOM